This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial (TRANSFUSE)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Australian Red Cross
Information provided by (Responsible Party):
David James Cooper, Australian and New Zealand Intensive Care Research Centre
ClinicalTrials.gov Identifier:
NCT01638416
First received: July 9, 2012
Last updated: February 9, 2017
Last verified: February 2017
  Purpose
In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.

Condition Intervention Phase
Transfusion Age of Blood Other: Blood transfusion Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units

Resource links provided by NLM:


Further study details as provided by David James Cooper, Australian and New Zealand Intensive Care Research Centre:

Primary Outcome Measures:
  • Mortality [ Time Frame: 90 Day ]
    Mortality at day 90


Secondary Outcome Measures:
  • Mortality [ Time Frame: 28 day ]
    28 day mortality

  • Persistent Organ Dysfunction combined with death [ Time Frame: day 28 ]
    Persistent Organ Dysfunction combined with death at 28

  • Days alive and free of mechanical ventilation [ Time Frame: day 90 post randomisation ]
  • Day alive and free of renal replacement therapy. [ Time Frame: day 90 post randomisation ]

Enrollment: 5000
Study Start Date: October 2012
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard of care
Blood Transfusion Standard of care- oldest blood.
Other: Blood transfusion
Blood transfusion in ICU patients aged 18 and over.
Arm B
Blood Transfusion Freshest blood.
Other: Blood transfusion
Blood transfusion in ICU patients aged 18 and over.

Detailed Description:

Inclusion criteria

•Patients hospitalised in ICU with an anticipated ICU stay of at least 24 hours, in whom the decision has been made by medical staff to transfuse at least one RBC unit.

Exclusion criteria

  • Age younger than 18
  • Previous RBC transfusion during the current hospital admission (including transfusion in another hospital for transferred patients)
  • Diagnosis of transplantation or hematologic diseases
  • Pregnancy
  • Cardiac surgery during the present hospital admission
  • Expected to die imminently (<24hrs)
  • The treating physician believes it is not in the best interest of the patient to be randomised in this trial.
  • Known objection to the administration of human blood products
  • Participation in a competing study

Primary outcome- 90 day mortality

Secondary outcome

  1. 28 day mortality
  2. Persistent Organ Dysfunction combined with death at 28 [47]
  3. Days alive and free of mechanical ventilation at day 90 post randomisation
  4. Day alive and free of renal replacement therapy at day 90 post randomisation
  5. Blood stream infection in ICU (post randomisation) defined using the Center for Disease Control and Prevention/National Healthcare Safety Network criteria [48]
  6. Length of stay in ICU and in hospital post randomisation
  7. Febrile non-haemolytic transfusion reactions
  8. EQ-5D score at Day 90 post randomisation [49]
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients hospitalised in ICU with an anticipated ICU stay of at least 24 hours, in whom the decision has been made by medical staff to transfuse at least one RBC unit.

Exclusion Criteria:

  • Age younger than 18
  • Previous RBC transfusion during the current hospital admission (including transfusion in another hospital for transferred patients)
  • Diagnosis of transplantation or hematologic diseases
  • Pregnancy
  • Cardiac surgery during the present hospital admission
  • Expected to die imminently (<24hrs)
  • The treating physician believes it is not in the best interest of the patient to be randomised in this trial.
  • Known objection to the administration of human blood products
  • Participation in a competing study (see below)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01638416

Locations
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Australian and New Zealand Intensive Care Research Centre
Australian Red Cross
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David James Cooper, Professor, Australian and New Zealand Intensive Care Research Centre
ClinicalTrials.gov Identifier: NCT01638416     History of Changes
Other Study ID Numbers: ANZICRCDJC006
Study First Received: July 9, 2012
Last Updated: February 9, 2017

ClinicalTrials.gov processed this record on June 28, 2017